Please login to the form below

Not currently logged in
Email:
Password:

BPR Pharma strengthens research team

Vicky Davies joins the UK-based international research agency from Bedrock Healthcare

Vicky DaviesUK-based international research agency BPR Pharma has appointed Vicky Davies as its new research director following 15 years partnering with pharmaceutical, medical device and consumer health clients.

Most recently, Davies headed up the insight department for Bedrock Communications as its research director.

She said: “I’m very excited to be joining Matt and Bridget on their quest to offer a more human approach to healthcare market research.

“BPR has a genuine interest and ability to understand people and their behaviour and their engaging, no nonsense deliverables give clients the means to move forward.”

Prior to her new role, Davies has worked in several senior research roles for agencies including Spinach and Morpace, as well as in-house for global devices manufacturer Coviden - now Medtronic.

BPR said: “Vicky is a hugely enthusiastic, creative researcher with a wealth of client-and agency-side experience.

“She shares our commitment to research excellence and understands the importance of engaging audiences in all aspects of the work we do.”

27th October 2017

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics